| Literature DB >> 22811686 |
Flavio Augusto de Carvalho1, Lee H Schwamm, Gustavo W Kuster, Monique Bueno Alves, Miguel Cendoroglo Neto, Gisele Sampaio Silva.
Abstract
BACKGROUND: Stroke is the fourth leading killer in the US, the first in Brazil and a leading cause of adult long-term disability in both countries. In spite of widespread recommendation, clinical practice guidelines have had limited effect on changing physician behavior. Recognizing that both knowledge and acceptance of guidelines do not necessarily imply guideline adherence, the American Heart Association/American Stroke Association (AHA/ASA) developed a national stroke quality improvement program, the 'Get With The Guidelines (GWTG) stroke'. Even though GWTG has produced remarkable results in the US, other countries have not adopted the program.Entities:
Keywords: Brazil; Get With The Guidelines stroke; Performance indicators; Quality of care
Year: 2012 PMID: 22811686 PMCID: PMC3398824 DOI: 10.1159/000339578
Source DB: PubMed Journal: Cerebrovasc Dis Extra ISSN: 1664-5456
GWTG stroke quality of care measures
| GWTG stroke quality of care measure | Measure definition for eligible patients |
| Intravenous rt-PA, 2 h | Patients presenting within 2 h of symptom onset who receive i.v. rt-PA within 3 h of symptom onset |
| Early antithrombotics | Antithrombotic therapy prescribed within 48 h of hospitalization, including antiplatelet or anticoagulant therapy but not DVT prophylaxis doses of subcutaneous heparins |
| DVT prophylaxis | Patients at risk for DVT (nonambulatory) who received DVT prophylaxis by the second hospital day, including warfarin sodium, heparin sodium, other anticoagulants or pneumatic compression devices |
| Antithrombotic medications | Antithrombotic therapy prescribed at discharge |
| Anticoagulants for patients with AFib | Anticoagulation therapy prescribed at discharge for patients with AF documented during the hospitalization, including therapeutic doses of warfarin, heparin, or other anticoagulant agents |
| LDL 100 | Lipid-lowering agent prescribed at discharge if LDL level is >100 mg/dl or patient taking lipid-lowering agents on admission |
| Smoking | Smoking cessation intervention (appropriate medication and/or counseling) provided at discharge |
Adapted from [8].
Eligible patients are those without any medical contraindications documented as reasons for nontreatment for each of the applicable measures. Discharge and subacute measures exclude patients who died. The acute rt-PA measures exclude patients with missing time of arrival, or treatment times.
Clinical characteristics of the 343 consecutive patients evaluated
| Characteristic (n = 343) | |
|---|---|
| Male | 58.7% |
| White | 84.4% |
| Black or Afro descendant | 3.8% |
| Mean age ± SD, years | 71.1 ± 14.4 |
| Hypertension | 59.7% |
| Diabetes mellitus | 33.7% |
| Dyslipidemia | 28.8% |
| Smoking prior to 1st month | 13.4% |
| Atrial fibrillation | 18.9% |
| Prior stroke | 26.5% |
| Coronary artery disease | 17.9% |
| Current stroke | 70.8% |
| Current transient ischemic attack | 29.2% |
Risk factors were considered if noted on the patient's chart or if medications for known risk factors were used before hospital admission or at discharge.
Comparison of the seven achievement measures data from the GWTG national database to our single institution database
| Performance measures | GWTG baseline data (2003) | GWTG data set (2007) | Our database (2008–2010) |
|---|---|---|---|
| Acute interventions | |||
| i.v. tPA for 2 h | 42.1% | 72.8% | 69.5% |
| Early antithrombotics | 91.5% | 97.0% | 98.2% |
| DVT prophylaxis | 73.8% | 89.5% | 100% |
| Discharge interventions | |||
| Smoking cessation | 65.2% | 93.6% | 66.6% |
| Anticoagulation for AFib | 95.0% | 98.4% | 86.7% |
| Discharge antithrombotics | 95.7% | 98.9% | 100% |
| Lipid-lowering drug for LDL-c 100 mg/dl | 73.6% | 88.3% | 56.1% |
LDL-c = Low-density lipoprotein cholesterol. * Not dosed.
Characteristics of patients who received or who did not receive lipid lowering treatment when eligible
| Compliance with lipid lowering recommendation | Yes | No | p |
|---|---|---|---|
| Mean age ± SD, years | 71.9 ± 12.9 | 69.2 ± 17.4 | 0.16 |
| Female gender | 39.9% | 44.8% | 0.40 |
| Hypertension | 65.5% | 47.6% | <0.01 |
| Diabetes mellitus | 39.1% | 21.9% | <0.01 |
| Coronary artery disease | 19.3% | 15.2% | 0.36 |
| AFib | 18.9% | 19.0% | 0.98 |
| Previous stroke | 26.9% | 25.7% | 0.82 |
| Previous TIA | 4.2% | 1.0% | 0.11 |
| TIA at presentation | 26.5% | 37.1% | 0.04 |
| Smoking | 13.4% | 13.3% | 0.97 |
| Followed by a neurologist | 81.5% | 76.2% | 0.25 |
Characteristics of patients who received or who did not receive lipid lowering treatment when eligible
| Anticoagulation for AFib when indicated | Yes | No | p |
|---|---|---|---|
| Mean age ± SD, years | 70.9 ± 14.4 | 75.73 ± 14.4 | 0.27 |
| Female gender | 42.2% | 18.2% | 0.11 |
| Hypertension | 59.6% | 72.7% | 0.38 |
| Diabetes mellitus | 33.4% | 45.5% | 0.40 |
| Coronary artery disease | 18.4% | 9.1% | 0.43 |
| Dyslipidemia | 28.6% | 36.4% | 0.57 |
| Previous stroke | 27.1% | 9.1% | 0.18 |
| Previous TIA | 3.3% | 0 | 0.53 |
| TIA at presentation | 29.8% | 27.3% | 0.85 |
| Smoking | 13.6% | 9.1% | 0.66 |
| Followed by a neurologist | 80.7% | 54.5% | 0.03 |
Fig. 1Factors associated with compliance to the adherence/eligibility index on a multivariate logistic regression model.